An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug product in a safety syringe or an auto injector with a reconstituted lyophilised drug product from a vial

Trial Profile

An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug product in a safety syringe or an auto injector with a reconstituted lyophilised drug product from a vial

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 2 Aug 2017 to 22 Aug 2017.
    • 07 Jun 2017 Planned primary completion date changed from 2 Aug 2017 to 22 Aug 2017.
    • 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top